The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.

@article{Stefanutti2015TheLE,
  title={The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - a post-hoc analysis of a Phase 3, single-arm, open-label trial.},
  author={Claudia Stefanutti and Dirk Jacobus Blom and Maurizio Rocco Averna and Emma A. Meagher and H dT Theron and Adrian David Marais and Robert A Hegele and Cesare R. Sirtori and Prediman Krishan Shah and Daniel Gaudet and Giovanni Battista Vigna and Bruce S. Sachais and Silvia Di Giacomo and Anna M E Du Plessis and Leanne T Bloedon and John P Balser and Daniel J. Rader and Marina A Cuchel},
  journal={Atherosclerosis},
  year={2015},
  volume={240 2},
  pages={408-14}
}
OBJECTIVE Lomitapide (a microsomal triglyceride transfer protein inhibitor) is an adjunctive treatment for homozygous familial hypercholesterolaemia (HoFH), a rare genetic condition characterised by elevated low-density lipoprotein-cholesterol (LDL-C), and premature, severe, accelerated atherosclerosis. Standard of care for HoFH includes lipid-lowering drugs and lipoprotein apheresis. We conducted a post-hoc analysis using data from a Phase 3 study to assess whether concomitant apheresis… CONTINUE READING